supported by the National Science Fund for Distinguished Young Scholars(32125013);the Excellent Young Scholars Fund(82422052);the National Natural Science Foundation of China(92253304,82002718,92357301,92253305,82461160322);the National Key R&D Program of China(2023YFC2506401);the Jiangsu Natural Science Foundation(BK20191077);the China National Postdoctoral Program for Innovative Talents(BX2021306,BX2024370);the Shanghai Oriental Talent Program,Shanghai Science and Technology Development Funds(22QA1409900,23ZR1470100);Shanghai Municipal Science and Technology Major Project,the Sanofi Scholarship and Heaye Program.
Epigenetic regulation profoundly influences the fate of cancer cells and their capacity to switch between lineages by modulating essential gene expression,thereby shaping tumor heterogeneity and therapy response.In ca...
National Key R&D Program of China(2019YFE0111300);National Natural Science Foundation of China(22220102001,22273049);Zhejiang Provincial Natural Science Foundation of China(LD22H300001).
As a major class of medicine for treating the lethal type of castration-resistant prostate cancer(PCa),long-term use of androgen receptor(AR)antagonists commonly leads to antiandrogen resistance.When AR signaling path...
Androgen deprivation therapy(ADT)is the standard of care treatment for advance stage prostate cancer.Treatment with ADT develops resistance in multiple ways leading to the development of castration-resistant prostate ...
This work was supported by the National Natural Science Foundation of China (NSFC 81672547, 81402110, and 81272820); Science and Technology Support Program of Sichuan Province (2015SZ0142); and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University.
Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undevel...
The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metas...
The aim of the present study was to determine whether oncologic outcomes and adverse events associated with active on/off intermittent antiandrogen monotherapy (daily bicalutamide, 50 mg per day) are comparable with...
Androgens and androgen receptors (AR) play a pivotal role in expression of the male phenotype. Several diseases, such as androgen insensitivity syndrome (AIS) and prostate cancer, are associated with alterations i...
Aim: To identify flutamide regulated genes in the rat ventral prostate. Methods: Total RNA from ventral prostates of control and flutamide treated rats were isolated. Differentially expressed transcripts were identi...
Aim: To evaluate the long-term effectiveness, side effects and compliance rates of two types of drugs (luteinizing hormone-releasing hormone [LHRH] agonist and antiandrogen) that were used individually to treat pat...
Objective\ To evaluate the response to antiandrogen withdrawal in patients with advanced prostate cancer treated with combined androgen blockade. Methods\ Twenty four cases of advanced prostate cancer (10 in stage C ...